Table 1 Used human serum samples in this study

Patients

Severe symptoms, hospitalized (ICU), unvaccinated

27 (7/20)

65 (39–86)

7–25 days after symptom onset (mean 12 days)

Vaccinated persons

2×BNT162b2 (Corminaty, BioNTech-Pfizer)

69 (40/29)

42 (23–66)

7–54 days after 2nd dose (mean 22 days)

2×mRNA-1273 (Spikevax, Moderna)

6 (2 /4)

38 (19–70)

5–55 days after 2nd dose (mean 26 days)

1×Ad26.COV2.S (Janssen COVID-19 vaccine, Johnson&Johnson)

6 (2/4)

35 (24–40)

14–33 days after 1st dose (mean 26 days)

2× BNT162b2 or 1×Ad26.COV2.S boosted by 1× BNT162b2 (or mRNA-1273)

34 (20/14)

39 (24–66)

5–49 days after 3rd/2nd dose (mean 19 days)